Second Sight Medical (NASDAQ: EYES) reported Q4 EPS of ($0.14), versus ($0.17) reported last year. Revenue for the quarter came in at $3.1 million versus the consensus estimate of $1.61 million (1 analyst).

“2017 was an important year for Second Sight in which we achieved significant revenue and implant growth, validating our Centers of Excellence strategy and strengthening our commercial platform. We expanded our reach into new markets around the world and established a solid funnel of candidates interested in our technology through our proactive U.S. patient outreach efforts. And we recently delivered on our most ambitious goal – implanting and activating the first-in-human subject in the Orion feasibility study. Building on our notable achievements, we are confident in our ability to advance our commercial, R&D and clinical research efforts and expand our market reach in 2018,” said Will McGuire, President and CEO of Second Sight.

For earnings history and earnings-related data on Second Sight Medical (EYES) click here.